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Abstract
Background: Sulfur mustard (SM) is a blister-forming agent that has been used as a chemical weapon. Sulfur
mustard can cause damage in various organs, especially the skin, respiratory system, and eyes. Generally, the
multiple complications of mustard gas result from its alkalizing potency; it reacts with cellular components like
DNA, RNA, proteins, and lipid membranes.
TGF-b is a multi-functional cytokine with multiple biological effects ranging from cell differentiation and growth
inhibition to extracellular matrix stimulation, immunosuppression, and immunomodulation. TGF-b has 3 isoforms
(TGF-b 1, 2, 3) and its signaling is mediated by its receptors: R1, R2 and intracellular Smads molecules.
TGF-b has been shown to have anti-inflammatory effects. TGF-bs and their receptors also have an important role in
modulation of skin inflammation, proliferation of epidermal cells, and wound healing, and they have been
implicated in different types of skin inflammatory disorders.
Methods: Seventeen exposed SM individuals (48.47 ± 9.3 years), 17 chronic dermatitis patients (46.52 ± 14.6 years),
and 5 normal controls (44.00 ± 14.6 years) were enrolled in this study.
Evaluation of TGF-bs and their receptors expressions was performed by semiquantitative RT-PCR. Only TGF1was
analyzed immunohistochemically.
Results: Our results showed significant decreases in the expression percentages of TGF-b 1, 2 and R1, R2 in
chemical victims in comparison with chronic dermatitis and normal subjects and significant decreases in the
intensity of R1 and R2 expressions in chemical victims in comparison with chronic dermatitis and normal controls.
(P value < 0.05)
Conclusions: TGF-bs and their receptors appear to have a noticeable role in chronic inflammatory skin lesions
caused by sulfur mustard.
Background
Sulfur mustard (SM) or mustard gas (bis-2-(chlor-
oethyl)) sulfide is a blister-forming agent that was used
as a chemical weapon [1] in World War I (1917) for the
f i r s tt i m ea n da g a i n s tI r a n i an citizens during the Iraq
Conflict (1980-1988), resulting in 100,000 chemically-
injured victims[2]. Currently, one-third of these victims
suffer from secondary complications [1]. SM can cause
damage to various organs, especially the skin, respiratory
tract, and eyes. In general, the various complications of
SM are caused by its alkylating effects on cellular com-
ponents such as DNA, RNA, and intramembranous pro-
teins and lipids, resulting in metabolic and genetic
damage [3-7].
In the skin, keratinocytes, particularly in the basal
layer, are the main target of SM alkylation [4,8]. The
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xerosis, hypo- or hyper-pigmentation, contact dermatitis,
and pruritus [9-12]. Cytokines have been shown to play
a key role in acute and chronic skin inflammation,
including chronic contact dermatitis due to SM [13-18].
One of these important cytokines is transforming
growth factor-b (TGF-b), a 25 KD molecular weight
(MW) homo-dimmer protein in its active form [19,20].
TGF-b has 3 isoforms (TGF-b 1, 2, 3), Its signaling is
mediated by its transmembrane receptors, TR1 and TR2,
which have serine/threonine kinase activity [21]. The
intracellular signaling pathway of TGF-b is mediated by
Smads molecules [22,23] that eventually enter the
nucleus, bind with transcription promoters/cofactors,
and regulate the transcription of DNA [24-27]. TGF-b is
secreted from several cell types such as T cells, macro-
phages, platelets, endothelial cells, keratinocytes, and
fibroblasts o[28,29]; it is a multi-functional cytokine
with biological effects ranging from cell differentiation
and growth inhibition to extracellular matrix stimula-
tion, immuno-suppression, and immuno-modulation
[29,30]. There have been data suggesting that the anti-
inflammatory effect of TGF-b on Th1 and Th2 produc-
tion and differentiation in macrophages and dendritic
cells is a key issue in the skin manifestations of SM
[21,27,31-38].
T oe v a l u a t et h ep o s s i b l er o l eo fT G F - b and its recep-
tors in chronic inflammatory skin lesions caused by SM
and symptoms like pruritus, we attempted to assess the
expression of TGF-b and its receptors in the skin lesions
of chemical-injured victims of SM in comparison with
normal controls.
Methods
Sampling
The subjects of this study were 17 male SM chemically-
injured patients between the ages of 38 and 70 without
an exposure history to toxic agents other than SM,
17 male chronic contact dermatitis patients between the
ages of 20 and 68 without history of exposure to SM,
and 5 healthy male participants between the ages of 21
and 58. The means and standard deviations (mean ±
SD) of age were 48.47 ± 9.3, 46.52 ± 14.6 and 44.00 ±
14.6 for MS chemically-injured patients, chronic contact
dermatitis patients and normal ones, respectively, and
there were no significant differences in ages among the
three groups (p > 0.05). The chemically-injured patients
had documented histories of exposure to SM during the
Iran-Iraq war (1983-88), and the chronic contact derma-
titis patients had sought ambulatory medical treatment
at a dermatology hospital. People with histories of
addiction or topical treatment during the 48 hours
before biopsy were excluded from the study. Informed
consent was obtained from all the patients and normal
men to be examined, and all of them were aware of the
probable consequences of a skin biopsy.
The severity of the pruritus was measured subjectively
by a pruritus scale (0-3). Score 0: no itching, Score 1:
mild itching but no significant disturbance of daily activ-
ities; Score 2: moderate itching causing disturbance of
daily activities; Score 3: severe itching causing distur-
bance in night sleep.
Biopsy specimens (3m m
2 size and about 25 mg
weight) were taken from pruritic plaque skin lesions
under topical anesthesia with 2% lidocaine and put into
trizol or 4% buffered paraformaldehyde.T h es a m p l e s
in trizol were transferred via -20°C rack to store at -80°C
until RNA extraction, while those in formalin were
placed in the refrigerator for fixation.
RNA extraction
Total RNA was harvested in conformity with manufac-
turer’s recommendations using trizol reagent (Invitrogen,
Carlsbad, CA). Briefly described, skin biopsy specimens
were homogenized in trizol by mean of an ultrasonic
homogenator. After adding 200 μl chloroform (Merck,
Germany) and centrifuging at 12,000 rpm, RNA contain-
ing homogenates in the aqueous phase were separated,
and the same volume of isopropranol was added. To avoid
contamination with proteins, the lowest fraction of the
aqueous phase was not incorporated into the total RNA
sample. Following centrifugation, precipitated RNA
was dissolved in ethanol at 75% and centrifuged again at
1200 rpm. Isolated RNA was eluted in 20 μl RNAase-free
water, and the quantity and integrity of RNA were measured
by Nano Drop (ND-1000 UV - Vis spectrophotometer).
Primer design
The primer sets for TGF-b1, TGF-b2, TGF-b receptor 1,
TGF-b receptor 2, and b-actin (control gene) are shown
in Table 1.
cDNA synthesis and Semi quantitative RT-PCR
Aliquots of 500 ng total RNA were reverse-transcribed
to create first-strand complementary DNA by super-
script III reverse-transcriptase (Invitrogen) according to
the manufacturer’s protocol. The resulting 1 μl of cDNA
was validated with PCR in a volume of 25 ml containing
2.5 μl buffer (10x Takara), 5pm deoxynucleoside tripho-
sphate, 0.3 μL rTq polymerase (Cinagene, Tehran, Iran)
a n d1 0p mp r i m e rm i x .P C Rw a sc a r r i e do u ti nt h e
same solution with heat held at 95°c for 3 min, dena-
turation at 95°c for 30 sec, and annealing at 59°C, 57°C,
58°C, 56°C, 57°C, or 59°C for TGF-b1, TGF-b2, TGF-b
receptor 1, TGF-b receptor 2, and b-actin, respectively,
for 30 sec, extension at 72°C for 1 min (33 cycle), term-
inal extension at 72°c for 5 min, and a terminal hold at
4°C. PCR products were separated by 2% agarose gel
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visually detectable under UV light after dying with ethi-
dium bromide. All results were normalized with b-actin
expression to compensate for differences in cDNA
amount. Image analysis (using Scion Image software)
was done to obtain quantitative data. (Scion Corpora-
tion, Frederick, MD)
Immunohistochemistry
Details of the immunohistochemistry are already described
elsewhere [39]. In brief, skin biopsy specimens were placed
in 4% buffered paraformaldehyde for fixation.
After immersion overnight in phosphate buffer con-
taining 30% sucrose, 20 μm thicktissue sections were cut
on a cryostat and incubated with HO-1 antibody (1:200
dilution in phosphate buffer) for 12 h at 4°C. The anti-
body used in this study was a mouse monoclonal IgG1
antibody raised against recombinant TGF-b1 of human
origin (Santa Cruz Biotechnology, Inc, USA) at a dilution
of 1:200. After incubation with the primary antibody, the
sections were washed with PBS and incubated with bioti-
nylated anti-mouse secondary antibody (Santa Cruz
Biotechnology, Inc, USA). Antigen-antibody reaction
sites were detectable using an ABC complex (avidin-
biotinylated peroxidase complex) system (Vector
Laboratory, Burlingame, CA, USA) with DAB as a sub-
strate. For the negative control, phosphate-buffered sal-
ine (PBS) was substituted for the primary antibody.
Statistical analysis
Data were analyzed by one-way ANOVA followed by a
Bonferroni’s test for multiple comparisons (using SPSS
version 13). A level of P < 0.05 was considered statistically
significant. All results were expressed as means ± SD.
Results
Clinical Findings
The pruritus scale level was severe (category 3) for all
patients previously exposed to SM, while that for the
chronic contact dermatitis patients varied from mild
(17.6%) to moderate (29.4%) and severe (53.0%) levels
(Table 2).
We also assessed dermal complications due to scratch-
ing in chemically injured and chronic contact dermatitis
patients (Table 3).
There were no significant differences in excoriation,
lichenification, erythema, or fissure between these two
patient groups (p > 0.05).
Molecular Biological Findings
Only two (11.7%) of the 17 SM chemically-injured
patient samples expressed the TGF-b1 gene, in contrast
to the chronic contact dermatitis patient samples (10 of
the 17 expressing it: 58.8%) and normal controls (4 of
the five expressing it: 80%), the significantly low expres-
sion rate among the three groups (p = 0.003). Only one
Table 1 Primer designs and sequences for TGF-b1 , TGF-b 2 , TGF-bR1 and TGF-bR2
Product size Annealing Time Sequence Name
242 bp 59 5’TCAAGCAGAGTACACACAGC3’ TGF-b1 Forward Primer
59 5’GCACAACTCCGGTGACATC3’ TGF-b1 Reverse Primer
220 bp 57 5’TTGACGTCTCAGCAATGGAG3’ TGF-b2 Forward Primer
57 5’TCAGTTACATCGAAGGAGAGC3’ TGF-b2 Reverse Primer
190 bp 56 5’TGCTGCAATCAGGACCATTG3’ TGF-bR1 Forward Primer
56 5’TCCTCTTCATTTGGCACTCG3’ TGF-bR1 Reverse Primer
210 bp 57 5’TGCTCACCTCCACAGTGATC3’ TGF-bR2 Forward Primer
57 5’TCTGGAGCCATGTATCTTGC3’ TGF-bR2 Reverse Primer
190 bp 59 5’TCATGAAGATCCTCACCGAG3’ b-actin Forward Primer
59 5’TTGCCAATGGTGATGACCTG3’ b-actin Reverse Primer
Table 2 Severity of pruritus according to the pruritus
scale in chemically-injured and chronic contact dermatitis
patients
Chemically-injured
patients
Chronic contact dermatitis
patients
Mild 0% 17.6%
Moderate 0% 29.4%
Severe 100% 53.0%
Table 3 Dermal complications due to scratching in
chemically-injured and chronic contact dermatitis
patients
chemically-injured
patients
chronic contact dermatitis
patients
Yes No Yes No
Excoriation 13 4 14 3
Lichenification 15 2 13 4
Erythema 14 3 14 3
Fissure 2 15 3 14
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expressed the TGF-b2 gene, in contrast to the chronic
contact dermatitis-patient samples (3 of the 17 expres-
sing it: 47%) and normal controls (4 of the five expres-
sing it: 80%); the expression rates among the three
groups were significantly different (p = 0.002).
As the numerical comparison for TGF-b receptors
reveals, only two (11.7%) of the 17 SM chemically-
injured patient samples expressed the TGF-b receptor1
gene in contrast to the chronic contact dermatitis
patient samples (13 of the 17 expressing it: 76.4%) and
the normal controls (4 of the five expressing it: 80%);
there were significant differences among the three
groups (p = 0.001). Two (11.7%) of the 17 SM chemi-
cally-injured patient samples expressed the TGF-b
receptor 2 gene in contrast to the chronic contact der-
matitis-patient samples (9 of the 17 expressing it: 52.9%)
and normal controls (4 of the five expressing it: 80%);
the expression rates among the three groups were signif-
icantly different (p = 0.006) (Figure 1).
With regard to the expression intensity measured by
densitometer (relative density of TGF-b gene/b-actin
gene), the expression intensities for TGF-b1a n d- b2
genes in the chemically-injured patient samples were
0.046 ± 0.15 and 0.013 ± 0.05, respectively, in contrast
to those in the chronic contact dermatitis-specimens
(1.105 ± 2.46 and 0.495 ± 0.88, respectively) and that in
normal ones (0.436 ± 0.74 and 0.309 ± 0.42, respec-
tively), with insignificantly low expression levels among
the three groups (p = 0.20 and p = 0.08 respectively).
The expression intensities for TGF-b receptor1 and 2
genes in the positive specimens of SM chemically-
injured patients were 0.046 ± 0.13 and 0.03 ± 00.08,
respectively, in contrast to those in the chronic contact
dermatitis patients (0.433 ± 0.45 and 0.523 ± 0.67,
respectively) and in the normal controls (0.848 ± 0.79
and 0.573 ± 0.70, respectively). The expression rates
among the three groups were significantly different (p =
0.001 and p = 0.01 respectively) (Figure 2, 3).
When the expression intensity and the severity of the
pruritis are compared, there was a tendency for patients
without genetic expression for TGF-b1 and TGF-b
receptor1 to have significantly increased severity (p =
0.04 and p = 0.01 respectively), but patients without
genetic expression for TGF -b2 and TGF-b receptor2
did not exhibit statistically significant increased severity
(p = 0.70 and p = 0.36 respectively) (Table 4).
Localization of TGF-b1 by immunohistochemistry
The expression/localization of TGF-b1, as a representa-
tive of the isoforms, was examined by immunohisto-
chemistry in the present study. In the normal skin of
controls, the immunoreactivity for TGF-b1w a si n t e n s e
throughout all the layers of the epidermis, and no
immunoreactivity is seen in the dermis (Figure 4-4A). In
contrast, TGF-b1-immunoreactivity was below the sig-
nificant detection level throughout both the epidermis,
which was increased in thickness (Figure 4-4C), and the
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Figure 1 Prevalence of expression of TGFb1, TGFb2, TGFR1, and TGFR2 in patients with chemical dermatitis, those with chronic
dermatitis, and normal individuals.
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hand, in the skin of SM-independent chronic dermatitis
patients, the immunoreactivity for TGF-b1w a si n t e n s e
in the basal layer and moderate to weak in the other
cell layers of the thickened epidermis (Figure 4-4B).
Discussion
Our results show that loss of expression of TGF-b1, TGF-
b2, TGF-b receptor 1, and TGF-b receptor 2 genes in che-
mically injured patients is significantly more severe than in
chronic contact dermatitis patients when compared with
normal controls. Additionally, the frequency of severely
pruritic cases is significantlyhigher in chemically injured
patients than in chronic contact dermatitis patients.
Sulfur mustard and its effects on skin inflammation and
the inflammatory cytokines have previously been exam-
ined in several different studies. In one animal study, the
response of inflammatory cytokines was assessed in
sulfur mustard-exposed mouse skin. The results empha-
sized the distinct role of IL-6 as a proinflammatory bio-
marker in sulfur mustard skin injury [13,14]. In another
study, alternations of gene expression of inflammatory
cytokines were detected in sulfur mustard exposed skin;
the results showed significant increases in the expression
of inflammatory cytokines (IL-1B, GM-CSF, IL-6) follow-
ing cutaneous sulfur mustard exposure [15].
It is well known that regulatory T lymphocytes pro-
duce TGF-b and that these cells may also prepare IL-10,
which, like TGF-b, has immunosuppressive effects [18].
In agreement with this fact, an interesting study has
shown that overexpression of IL-10 following exposure
to sulfur mustard can suppress the proinflammatory
cytokines (IL-8 and IL-6) in human epidermal keratino-
cytes and lead to delayed cell death [40]. These findings
are in agreement with our research results showing that
TGF-b,l i k eI L - 1 0 ,c a na l s oh a v ead i s t i n c tr o l ei nt h e
modulation of skin inflammation of mustard gas. Loss
of expression of TGF-bs and their receptors in the skin
lesions of chemical victims may lead to retention of
inflammation in the skin and chronic skin manifesta-
tions like pruritus because of lack of TGF-b control.
An animal investigation clearly reports that remark-
able inflammatory lesions are detected in many organs
of TGF-b1-negative mice [35]. Moreover, severe
immune pathology was detected in TGF-b knockout
mice [30], supporting our results.
The importance of the antiinflammatory role of TGF-
b has been also emphasized in studies of signaling path-
way mediators like Smad 3. These reports testify to this
fact that TGF-b signaling via Smad 3 has an important
role in modulation of inflammation in atopic and
1         2          3          4         5           6         7         8       9         10       11       12
Normal Dermatitis Chemical
TGFβ1 
TGFβ2
TGFβR1
TGFβR2
βactin
Figure 2 Gene expression of TGFb1, TGFb2, TGFR1, TGFR2 and
bactin in patients with chemical dermatitis, those with chronic
dermatitis, and normal individuals measured by semi-
quantitative RT-PCR. TGFb1 = 242 bp, TGFb2 = 220 bp, TGFR1 =
190 bp, TGFR2 = 210 bp and bactin = 190 bp.
Figure 3 Relative density of TGF-b genes/b-actin gene as expression ratios measured by Scion-image software in patients with
chemical dermatitis, those with chronic dermatitis, and normal individuals; the error bars show standard deviation (SD).
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tors bridle the inflammation flares mediated by other
cytokines, chemokines, and inflammatory cells. In future
studies, Smad molecules should be examined as possible
targets in the skin lesions of chemical victims.
In some other studies, it has been demonstrated that
TGF-b has a important in wound healing; thus we see
delays in wound healing in TGFb1-knockout mice [45].
This finding suggests that loss of expression of the
TGF-b family in skin lesions of mustard gas may explain
the chronic skin complaints of these patients.
Various studies have checked the expression of TGF-b
family and their receptors in normal skin and different
regions; most of them agree that the expression of TGFb1,
2, 3 and TGF-b R1, TGF-b R2 (as mRNA or protein
levels) is detectable in human keratinocytes and layers of
the skin. Our investigation also detected this expression at
the mRNA and protein levels, particularly in normal sam-
ples which usually express TGF-bs and their receptors.
Matrix - Metallo proteinases (MMPs) also have a role in
the inflammatory processes of sulfur mustard [50]; other
research has shown that TGF-b can inhibit MMPs [29,51].
Without the inhibitory control of TGF-bs, these MMPs
can be expected to continue their inflammatory effects. It
has also been suggested that a lack of TGF-b may play an
important role in both hyperproliferation and malignant
conversion in the skin and skin tumors [52].
Paradoxically, a few studies have described proinflam-
matory mechanisms of TGF-b in skin pathologic condi-
tions and its effects on chemo attraction [30,53-55].
These studies question the overall assumption that
TGF-b primarily has anti-inflammatory and immuno-
modulatory effects. Future investigations should clearly
focus on analyzing TGF-b roles in immunopathological
processes.
Finally, it is important to consider studies which have
assessed some therapeutic approaches to this type of
poisoning. The use of anti-oxidants and inhibitors of
NF-Kappab has been shown to be beneficial for sulfur
mustard treated human keratinocytes [56,57].
Moreover, another study has suggested that the
TGF-b/Smad pathway can be useful in the treatment of
atopic dermatitis [44].
Some other investigations have focused on the induc-
tion of TGF-b1 and TGF-b2 secretion by retinoic acid
(isotretinoin) [58], which can lead to inhibitory effects of
TGF-b on both inflammation and proliferation in the
skin [59,60]. Calcipotriol (a vitamin D3 analogue) has
been described to increase the secretion and activation
of TGF-b1a n dT G F - b2i nm u r i n es k i nc e l l s[ 6 1 ] .I n
another study, tacrolimus ointment (FK506) appeared to
upregulate TGF-b release in keratinocytes as a treatment
goal in dermatitis; this again reinforces an anti-inflam-
matory role for TGF-b in skin disorders [62,63].
These therapeutic studies may help us in future investi-
gations targeting the TGF-b family and its signaling path-
way and designed to cure or diminish the chronic skin
manifestations of sulfur mustard damage, including
chronic pruritus, which is resistant to common remedies.
Conclusions
In summary, we clarified that most chemically injured
patients did not express TGF-b1, TGF-b2, TGF-b
Table 4 The relation between expression of TGF-b genes
and severity of pruritus (1: mild, 2: moderate and 3:
severe) in all patients
Expression
of TGEb
receptor 2
Expression
of TGEb
receptor 1
Expression
of TGF-b2
Expression
of TGF-b1
Severity
of
pruritus
Num
++- - 3 1
---- 3 2
---- 3 3
---- 3 4
---- 3 5
---+ 3 6
---- 3 7
---+ 3 8
---- 3 9
---- 3 1 0
-+-- 3 1 1
---- 3 1 2
---- 3 1 3
---- 3 1 4
+-+- 3 1 5
---- 3 1 6
---- 3 1 7
++++ 3 1 8
++++ 2 1 9
++-+ 3 2 0
++++ 1 2 1
+++- 3 2 2
---- 3 2 3
-+-- 2 2 4
++-+ 1 2 5
++++ 3 2 6
-+++ 2 2 7
--+- 3 2 8
---- 2 2 9
---- 3 3 0
++++ 3 3 1
-+-+ 1 3 2
-+-- 2 3 3
++-+ 3 3 4
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patients have severe pruritus as a chief complaint.
Nevertheless, detailed information about mustard gas
effects on human skin, particularly at the molecular
level, is very limited, and this investigation with such a
small sample size cannot answer all the remaining ques-
tions. However, it can serve as a trigger for new research
examining the molecular pathology of SM skin injury
and thus developing new therapeutic approaches.
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